Societe Generale Effekten (S29798) Trades

TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) executive chairman Kirill Klip talked with Proactive's Stephen Gunnion about the company’s latest developments, including a key milestone in its transition to a cash-flow-generating royalty business. Klip highlighted that TNR Gold holds royalties on significant projects, including the Los Azules Copper project and the Mariana Lithium project in Argentina. With Los Azules now applying for Argentina's incentive regime for large investments, he explained that the project could see substantial tax reductions, making it easier to attract the $2.7 billion investment required for construction. Discussing Argentina’s economic reforms under President Javier Milei, Klip noted that the country's policies are encouraging large-scale investment in the mining sector. He also pointed to the environmental permit secured for Los Azules, bringing it closer to a construction decision, with a feasibility study expected in the first half of the year. Klip also shared insights from Fundamental Research Corporation’s latest analysis, which increased its price target for TNR Gold from $0.24 to $0.28, underscoring the company's transition from a project generator to a cash-flow-generating royalty company. Watch the full interview for more insights into TNR Gold’s latest developments. For more interviews like this, subscribe to Proactive’s YouTube channel, give this video a like, and turn on notifications for future updates! #TNRGold #MiningInvesting #LosAzules #CopperMining #LithiumInvesting #MiningStocks #ArgentinaMining #RoyaltyCompany #StockMarket #JavierMilei

GraphEnergyTech CEO Dr Thomas Baumeler discussed a collaboration with the Taiwan Perovskite Solar Corporation, Taiwan’s prestigious Industrial Technology Research Institute and the University of Cambridge. The project is supported by an Innovate UK grant worth nearly £900,000. Known as GETPSC (Graphene Electrode Technology for Perovskite Solar Cells), Baumeler explained that current solar cells rely on expensive silver electrodes, which degrade when in contact with Perovskite Solar Cells. GraphEnergyTech, a Frontier IP Group PLC (AIM:FIPP) portfolio company, aims to replace these with graphene-based electrodes, offering a more stable and cost-effective alternative. "Graphene is one of the most interesting materials out there," he said, highlighting its durability and lower cost compared to silver. Perovskite Solar Cells are considered the next major advancement in photovoltaics due to their efficiency and simpler manufacturing process. However, industrial-scale adoption has been hindered by the lack of a viable nonmetallic electrode—something GraphEnergyTech aims to solve. Baumeler also noted that GraphEnergyTech is working on replacing silver electrodes in traditional silicon-based solar cells while exploring applications for its conductive carbon-based technology in batteries, supercapacitors, and electronics. For more insights into renewable energy innovations, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future updates. #GraphEnergyTech #SolarEnergy #GrapheneTech #PerovskiteSolar #RenewableEnergy #CleanEnergy #TechInnovation #SolarCells #GreenTechnology #EnergyStorage

Digitalbox PLC CEO James Carter talked with Proactive's Stephen Gunnion about the company's potential acquisition of The Life Network. Carter explained that this move aligns with Digitalbox’s previous acquisition strategy, referencing the success of 99 Problems, which significantly boosted engagement on The Tab. He highlighted that the company is currently in a test phase for The Life Network, evaluating audience engagement and monetisation potential before finalising the acquisition. Digitalbox will assess key metrics, including website traffic and on-platform engagement, as they aim to replicate past successes. Carter also discussed how the acquisition fits into Digitalbox’s broader strategy, particularly in targeting a US female audience. He noted that the company has seen growth in the US through its Royal Insider brand and believes The Life Network’s audience composition offers a strong opportunity to expand this presence. Additionally, with over £2 million in cash reserves, Carter confirmed that Digitalbox is actively seeking further acquisitions, having already completed five deals in the past four months. He emphasised that the company remains focused on both acquiring and organically growing its assets to drive long-term value. For more insights from industry leaders, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications for future updates! #DigitalboxPLC #JamesCarter #MediaAcquisition #SocialMediaGrowth #TheLifeNetwork #DigitalMedia #ContentMonetization #InvestorNews #USMarket #RoyalInsider

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection